"Lansoprazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Descriptor ID |
D064747
|
| MeSH Number(s) |
D02.886.640.074.249 D03.383.725.024.249 D03.633.100.103.034.249
|
| Concept/Terms |
Lansoprazole- Lansoprazole
- Lansoprazol
- 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
- Lansoprazoles
|
Below are MeSH descriptors whose meaning is more general than "Lansoprazole".
Below are MeSH descriptors whose meaning is more specific than "Lansoprazole".
This graph shows the total number of publications written about "Lansoprazole" by people in this website by year, and whether "Lansoprazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lansoprazole" by people in Profiles.
-
Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects ?-catenin distribution. Clin Cancer Res. 2013 Jul 15; 19(14):3966-76.
-
The acidity index: a simple approach to the measurement of gastric acidity. Aliment Pharmacol Ther. 2004 Feb 15; 19(4):443-8.
-
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002 Mar; 97(3):575-83.
-
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther. 2001 May; 15(5):647-52.
-
Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther. 2001 Apr; 15(4):519-24.
-
Aggressive acid control: minimizing progression of Barrett's esophagus. Am J Manag Care. 2001 Feb; 7(1 Suppl):S15-8.
-
Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000 Oct; 14(10):1267-72.
-
Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000 Jun; 14(6):709-14.
-
Importance of adequate acid suppression in the management of Barrett's esophagus. Gastroenterology. 1999 Dec; 117(6):1509-10.
-
Medical therapy. Management of the refractory patient. Gastroenterol Clin North Am. 1999 Dec; 28(4):847-60.